TLDR:
- Eyenovia invests $ 50 million in Hyperliquid (HYPE) and becomes the first public US company with Native Token Treasury
- New Cio Hyunsu Jung will lead Blockchain strategy and validator expansion
- Company to Rebrand as Hyperion Defi and adopt Ticker Hypd along with biotechnology operations
- Validator role through Anchorage aims to earn exchange and secure hyperliquid blockchain
Eyenovia has taken a historic step to merge traditional financing with web3. The Nasdaq-listed biotechnology company announced an investment of $ 50 million to Buy Hype -Tokens from Hyperliquidblockchain. This feature makes it the first American public company that includes a native crypto in its Treasury.
The company aims to secure validator status in the Hyperliquid network. Investors and crypto enthusiasts see this as a turning point for institutional blockchain assumption.
$ 50 million collected to launch Hyperliquid Crypto Treasury
Eyenovia revealed their $ 50 million Private investment agreement in an edition on June 17. According to the company, this financing round was led by institutional accredited investors.
Revenue will support their crypto reserve strategy, completely focused on acquiring over 1 million hype tokens.
The company will issue Convertible preferred layer and warrants, priced at $ 3.25 per share. If they are fully exercised, warrants can receive another $ 150 million. Eyenovia expects the transaction to be closed off June 20, pending standard terms.
As part of this transition, Eyenovia Hyunsu Jung appointed Head of Investment Manager and a new board member. His role will focus on controlling the Crypto Treasury initiative. Jung said that the company chose hype because of its strong basic factors and rising network performance.
The investment positions Eyenovia as one of the largest global validators on Hyperliquid -Blockchain.
The company also plans to invest its hype holding through Anchorage Digital for safe handling. This validator position will offer both return possibilities and a role in maintaining blockchain’s safety.
Strategic Rebrand and continued activity
In parallel, Eyenovia will continue with its biotechnology roadmap. It is still involved in the development of its GEN-2 Optejet device, which it aims to register with the FDA in September.
The company also examines commercial partnerships for the unit’s launch.
In addition to its crypto strategy, Eyenovia plans to reclassify to the “Hyperion Defi” and adopt the ticker “Hypd.” This shift signals a broader vision that adapts both its health care innovations and Blockchain goals.
🇺🇸 Nasdaq-listed Eyenovia collected only $ 50 million to buy $ Hype Tokens-flash the first US public company to have a web3-in-born token in its balance sheet.
Wall Street is no longer just looking.
They buy. 🔥#Hyp pic.twitter.com/d4eohrz2i22– Crypto Patel (@cryptopatel) June 18, 2025
Crypto commentator Crypto Patel noted that Wall Street no longer looks from the sideline. He shared that Eyenovia’s bold crypto movement could inspire similar measures from other listed companies.
